Similarly, alterations in the estrogen receptor alpha gene (ESR1), such as amplification, mutations, and rearrangements, drive therapeutic resistance and metastasis in estrogen receptor positive (ER+) breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.